Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Duffau

Showing results (61-70 of 113) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|December 19, 2021
Incidence of lung and human papilloma virus-associated malignancies in HIV-infected patientsHélène Chaussade, Fabien Le Marec, Gaëlle Coureau, et al.
Health and Quality of Life Outcomes|July 12, 2020
Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliV ancillary studyDiana Barger, Mojgan Hessamfar, Didier Neau, et al.
Scientific Reports|April 17, 2022
A comprehensive analysis of excess depressive disorder in women and men living with HIV in France compared to the general populationVictor Hémar, Mojgan Hessamfar, Didier Neau, et al.
The American Journal of Medicine|October 18, 2025
TRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costsEtienne Rivière, Olivier Mansier, Alexandre Guy, et al.
Autoimmunity Reviews|July 18, 2021
Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritisGuillermo Ruiz-Irastorza, Luis Dueña-Bartolome, Susanna Dunder, et al.
AIDS (London, England)|November 7, 2015
Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patientsPierre Duffau, Linda Wittkop, Estibaliz Lazaro, et al.
International Journal of Antimicrobial Agents|December 5, 2022
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018Elsa Nyamankolly, Pantxika Bellecave, Linda Wittkop, et al.
Rheumatology (Oxford, England)|March 25, 2017
Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor κB and its ligand signalling in rheumatoid arthritisAnne Contis, Stéphane Mitrovic, Julie Lavie, et al.
Joint Bone Spine|February 26, 2023
Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational studyLéa Lopez, Thomas Barnetche, Gael Galli, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2009
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine CohortLinda Wittkop, Dominique Breilh, Daniel Da Silva, et al.
Pageof 12

Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|December 19, 2021
Incidence of lung and human papilloma virus-associated malignancies in HIV-infected patientsHélène Chaussade, Fabien Le Marec, Gaëlle Coureau, et al.
Health and Quality of Life Outcomes|July 12, 2020
Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliV ancillary studyDiana Barger, Mojgan Hessamfar, Didier Neau, et al.
Scientific Reports|April 17, 2022
A comprehensive analysis of excess depressive disorder in women and men living with HIV in France compared to the general populationVictor Hémar, Mojgan Hessamfar, Didier Neau, et al.
The American Journal of Medicine|October 18, 2025
TRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costsEtienne Rivière, Olivier Mansier, Alexandre Guy, et al.
Autoimmunity Reviews|July 18, 2021
Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritisGuillermo Ruiz-Irastorza, Luis Dueña-Bartolome, Susanna Dunder, et al.
AIDS (London, England)|November 7, 2015
Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patientsPierre Duffau, Linda Wittkop, Estibaliz Lazaro, et al.
International Journal of Antimicrobial Agents|December 5, 2022
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018Elsa Nyamankolly, Pantxika Bellecave, Linda Wittkop, et al.
Rheumatology (Oxford, England)|March 25, 2017
Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor κB and its ligand signalling in rheumatoid arthritisAnne Contis, Stéphane Mitrovic, Julie Lavie, et al.
Joint Bone Spine|February 26, 2023
Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational studyLéa Lopez, Thomas Barnetche, Gael Galli, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2009
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine CohortLinda Wittkop, Dominique Breilh, Daniel Da Silva, et al.
Pageof 12